There is a new blood test that proved to be better than current tests. It’s called the MR-proADM test and it identifies heart failure patients in most dire need of treatment when they turn up at an Emergency Room complaining of shortness of breath. The test succeeded at demonstrating superiority over what is considered to be the gold standard.
Developed by a privately held German company called Brahms AG, it was approved for use in Europe on October 1. The Brahms test will be submitted to the U.S. Food and Drug Administration before year end to seek approval.
“I think that this is clearly significantly better than what we have now,” Dr. W. Frank Peacock of the Cleveland Clinic, one of the study’s lead investigators, said in an interview. “It raises the bar.”
“If approved in the U.S., the MR-proADM test will help ensure patients are accurately diagnosed and rapidly receive the treatment they need,” Peacock said.